Acquired Kronos Pipeline Assets

About Ignota Labs

Ignota Labs operates at the intersection of AI and drug development, focusing on the significant problem of clinical trial failure due to toxicity. The company has developed SAFEPATH, a first-of-its-kind AI platform that integrates cheminformatics and bioinformatics data to provide a mechanistic understanding of drug safety issues and propose actionable solutions for drug turnaround. By acquiring and revitalizing shelved programs from other companies, Ignota seeks to build a robust pipeline of de-risked assets, offering a potentially faster and more capital-efficient path to bringing new therapies to patients. The company is led by a co-founding team with strong backgrounds in AI, data science, biochemistry, and business strategy.

Other Not Specified Drugs